Nordic Life Science 1
TOP STORIES BUSINESS ACQU I SITIONS // AGREEMENTS
// COLLABORATIONS USD 2 MILLION … B U S IN E S S … has been awarded to TILT Biotherapeutics from the U.S. Department of Defense for a three-year project on treatment of ovarian cancer using the company’s TILT-123 asset. Alligator Bioscience restructures The company plans to restructure and reduce its workforce by 20-25%, with expected annual costs savings of SEK 20 million. R&D ALZECURE SELECTS NEW DRUG CANDIDATE The company has selected a TrkA-NAM drug candidate, ACD137, and started the preclinical development phase with the compound. ACD137 IS BEING developed within the TrkA-NAM project in AlzeCure’s Painless platform, with the aim of developing a new painrelieving drug for the treatment of osteoarthritis and other severe pain conditions. A drug candidate from the project has now been selected to proceed into the preclinical development program, which includes safety and tolerability studies, as well as formulation work and stability testing. “There is great interest from the pharmaceutical industry in this target mechanism, and the fact that we have such a potent and selective substance is a decisive advantage, as several big pharma companies have tried to develop TrkA-NAM assets," says Martin Jönsson, CEO, AlzeCure, and adds: "In indications such as knee osteoarthritis, there are also large medical needs and a growing patient group." NLS Søren Bregenholt, CEO, Alligator Bioscience "OVER THE LAST 12 months our OPTIMIZE-1 trial evaluating our lead asset mitazalimab in pancreatic cancer has delivered two sets of highly encouraging interim data as well as fasterthan-expected patient recruitment leading to an accelerated top-line readout. We now need to remain laser focused on our objective to deliver outstanding returns to our stakeholders and to maximize the chances of developing innovative therapies in an ever more challenging biotech environment. Unfortunately, this initiative will affect our most important asset, our colleagues who have strived professionally and diligently to allow Alligator to deliver on our mission,” states Søren Bregenholt, CEO, Alligator Bioscience. NLS 16 | NORDICLIFESCIENCE.ORG PHOTO JENNY LAGERQVIST